医学
内科学
心肌梗塞
四分位数
前瞻性队列研究
C反应蛋白
心脏病学
入射(几何)
队列研究
风险因素
炎症
置信区间
物理
光学
作者
Guyu Zeng,Ce Zhang,Ying Song,Zheng Zhang,Jingjing Xu,Zhenyu Liu,Xiaofang Tang,Xiaozeng Wang,Yan Chen,Yongzhen Zhang,Pei Zhu,Xiaogang Guo,Lin Jiang,Zhifang Wang,Ru Liu,Qingsheng Wang,Yi Yao,Yingqing Feng,Yaling Han,Jinqing Yuan
出处
期刊:BMC Medicine
[Springer Nature]
日期:2024-12-23
卷期号:22 (1)
标识
DOI:10.1186/s12916-024-03823-z
摘要
Low-density lipoprotein cholesterol (LDL-C) is a well-recognized risk factor for cardiovascular diseases. However, several clinical studies demonstrated an inverse association between LDL-C and mortality risk in patients with acute myocardial infarction (AMI), known as the lipid paradox. This study aims to investigate the potential impact of inflammation on the association between LDL-C levels and mortality risks. A total of 5244 patients with AMI from a large nationwide prospective cohort were included in our analysis. Patients were stratified according to LDL-C quartiles. The primary outcome was all-cause mortality, and the secondary endpoint was cardiac mortality. High-sensitive C-reactive protein (hsCRP) > 3 mg/L was defined as high inflammatory risk. During a median follow-up of 2.07 years, 297 mortality events (5.5%) and 227 cardiac mortality events (4.2%) occurred. Patients in the lowest LDL-C quartile had the highest incidence of all-cause mortality (7.3%) and cardiac mortality (5.8%). A U-shaped association between LDL-C levels and mortality risk was observed after multivariable adjustment, which persisted only in patients with high hsCRP levels. In contrast, a linear association between LDL-C and mortality risk was shown in patients with low hsCRP levels. AMI patients with lower LDL-C levels had a higher risk of mortality. However, this association was only observed in those with high inflammatory risk. In contrast, the relationship between LDL-C and mortality risk was linear in patients with low inflammatory risk. This suggests the importance of considering inflammation when managing LDL-C levels in AMI patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI